Independent business intelligence for the life sciences sector
PUBLICATIONS

Below, we provide a list of Beremans publications in reverse order of date, with links to corresponding pdfs:

Publications from 2011

Clinical phase drug development pipeline of UK / Ireland biotechnology companies: In Sep 2011, Beremans released a report identifying all UK / Ireland biotechnology companies with drug candidates that have entered clinical trials. All clinical phase drug candidates being developed by these companies are listed, both by clinical trial phase and by the category of disease (ICD-10) that they are intended to address. The report includes a table which briefly outlines each company (public/private status, geographic location, web address, focus of activity, pipeline summary). Therefore, the report contains information likely to be of use to, inter alia, parties contemplating licensing, merger or acquisition activity in the UK/Ireland biotechnology sector, or parties intending to provide products or services to companies in this sector.

Publications from 2010

Malaria vaccines: commercial prospects and landscape analysis: In July 2010, Beremans published a detailed analysis of the market landscape and commercial prospects for malaria vaccines. This report includes an examination of the clinical need for a vaccine (nature of disease, independent estimation of global incidence, identification and quantification of at-risk populations worldwide), an outline of the scientific / technological background (including key issues in malaria vaccine development), an assessment of the competitive environment (including analysis of the competitive positioning of the various clinical-stage vaccine candidates), quantification and 2020 projections of total potential end-users of a malaria vaccine (namely, travellers from >20 developed economies to particular regions of malaria transmission; private sector users in malaria transmission regions; and public sector users in malaria transmission regions), and 2020 revenue projections for a malaria vaccine, broken down by private sector sales in the developed world, private sector sales in the developing world, and public sector sales in the developing world, under particular vaccine price assumptions. There is also a provisional outline analysis of the military market for malaria vaccines.

Recent progress in dengue vaccine research and development: An invited review written by Beremans has been published in the peer-reviewed journal Current Opinion in Molecular Therapeutics (Curr Opin Mol Ther. 2010;12(1):31-8). Being invited to write a review on this topic for a Current Opinion journal is an indication of Beremans’ reputation in the vaccine field, especially with regard to vaccines relevant to travellers. It supports the claim that Beremans follows and understands the implications of critical developments in the areas in which it specialises, which enables the company to execute business intelligence projects from a position of strength. Having a good understanding of the science and technology of dengue vaccine development of course feeds into other projects, not least the Beremans report on the commercial prospects for dengue vaccines, which is a highly detailed market assessment based on, inter alia, a proprietary model of international travel from over 20 developed economies to over 100 endemic countries.

Publications from 2009

Commercial prospects for dengue vaccines: In November 2009, Beremans published a detailed analysis of the commercial prospects and market landscape for dengue vaccines. This report, which is available for purchase here, includes an examination of the clinical need for a vaccine (nature of disease, independent estimation of global incidence, identification and quantification of at-risk populations worldwide), an outline of the scientific / technological background (including key issues in dengue vaccine development), an assessment of the competitive environment, quantification and 2020 projections of total potential end-users of a dengue vaccine (namely, travellers from all developed economies to all regions of dengue transmission; private sector users in dengue transmission regions; and public sector users in dengue transmission regions), and 2020 revenue projections for a dengue vaccine, broken down by private sector sales in the developed world, private sector sales in the developing world, and public sector sales in the developing world.

BACR Interview #4: In the fourth of our series of interviews with BACR entrepreneurs, Dr. Nick Miller interviews Professor Paul Workman, who has been instrumental in the formation of two biotechnology companies, Chroma Therapeutics and Piramed Pharma. This interview focuses on Piramed, which was acquired by Roche in 2008; Chroma Therapeutics will be the subject of a later discussion.  In his academic life, Paul is Director of the Cancer Research UK Centre for Cancer Therapeutics and Harrap Professor of Pharmacology and Therapeutics at The Institute for Cancer Research, Sutton.

Publications from 2008

Cardiotoxicity Report; Beremans Ltd and Insight Pharma Reports (Cambridge Healthtech Institute, Boston, USA) have collaborated to publish a report on drug-induced cardiotoxicity. The report discusses methods, products and services designed to identify cardiotoxic compounds before they reach the market; discusses the current and possible future regulatory environment; outlines main commercial competitors; and suggests broad types of commercial opportunity in this subsector. The primary focus is on identification of drug-induced proarrhythmia, but some discussion is provided on identification of other forms of cardiotoxicity

Publications from 2007

Beremans data published in JTM; Data generated in a Beremans market research study have been published in the Journal of Travel Medicine (2007) 14:158-167. The paper, entitled “Current perceptions of Traveller’s Diarrhoea treatments and vaccines: results from a postal questionnaire survey and physician interviews”, presents an analysis of UK and US physicians’ perceptions of currently available Traveller’s Diarrhoea (TD) products, of hypothesised TD vaccines, and of aspects of travellers’ behaviour pertinent to the travel vaccine market. The abstract, and a link to the full paper, can be viewed here.

BACR Interview #3: In the third of our series of interviews with BACR personnel who are commercialising their research, Dr. Nick Miller interviews Professor Len Seymour whose research is being commercialised through Hybrid Sytems Ltd (www.hybridsystems.co.uk). Professor Seymour is Professor of Genetic Therapies in the Department of Clinical Pharmacology, University of Oxford, Head of the Cancer Research UK Gene Delivery Group, President of the British Society of Gene Therapy, and Supernumerary Fellow of Wolfson College, Oxford.

Publications from 2006

BACR Interview #2: Dr. Nicholas Miller interviews the founder of KuDOS Pharmaceuticals Limited, a company developing cancer therapies including inhibitors of DNA repair pathways.

BACR Interview #1: Dr. Nicholas Miller interviews founders of Biostatus Ltd, a company which is commercialising some of the discoveries of BACR members Laurence Patterson and Paul Smith, in particular novel molecular probes.

Travellers’ Diarrhoea Vaccines – a good run for your money?
Written by Nicholas Miller and Ingelise Saunders

Publications from 2005

Fair of face, foul of heart - cardiotoxicity and drug development
Written by Nick Miller

Vive la difference – genetic variation and drug development
Written by Nick Miller

Publications from 2004

The point of prefilled syringes
Written by Alex Hoffman

Stem cells – can blank slates become blank cheques?
Written by Sebastian Quist

The misfolding diseases unfold
Written by Nick Miller

RNA interference therapies – a RISCy business?
Written by Alex Hoffman

To sleep, perchance.....
Written by Nick Miller

Shibboleths in the accents of cancer
Written by Sebastian Quist

The drug discovery process-space and time in the pharmaceutical universe
Written by Nick Miller and Mohammad Afshar

Computational challenges for drug discovery: transforming data into knowledge
Written by Mohammad Afshar and Nick Miller

Whole cell hard sell – high content screening in drug discovery
Written by Paul Smith and Nick Miller